Clinical Trial Update: Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating a patient-derived autologous B7-H3 CAR-T cell therapy in previously treated extensive-stage small cell lung cancer with recu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Extrapulmonary Neuroendocrine Carcinoma

Drugs mentioned

• Autologous B7-H3 CAR T cells (CAR T cells targeting B7-H3)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma | Phase 1 | Status: NOT_YET_RECRUITING